Close Icon
We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Trusted Pharmaceutical Partnerships

Pharma Intelligence delivers the essential resources and event-driven insight trusted most by the world’s top companies and CROs in the pharma industry.

Trusted partnership

Bring drugs to market more efficiently with authoritative and reliable intelligence from Informa Pharma Intelligence. From micro analysis to competitor intelligence, Pharma Intelligence gives you the solutions you need to secure your place at the top of the market.

Join the legions of pharmaceutical companies, biotechs, and contract research organizations that rely on the timely and accurate data and insights from Pharma Intelligence to:

Keep in tune with the current landscape for pharma R&D with a free, information-packed webinar recording from Informa Pharma Intelligence. In the Global Pharma R&D Review webinar, our experts hit all the right notes as they used a music theme to explore key issues affecting R&D today, and offer a glimpse of what the rest of 2018 may look like.

Companion diagnostics are poised to be a huge growth area worldwide, with a CAGR of 20.1% over the next 5 years, making it a $6B industry by 2022. These often in-vitro medical devices provide essential information for the efficacy of a corresponding drug or biological product, and are also used for pre-determining the efficacy of treatment. Their growth is being propelled in most countries by a number of favorable factors.

As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?

While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.

The most surprising proposal coming out the Rose Garden drug pricing event was a call for disclosure of prices in DTC ads. As a policy idea, it may be a dud – but that doesn’t mean it isn’t a critical element of the plan.

The European Medicines Agency has started the difficult task of finding replacements for the UK chairs and members of its numerous working parties and groups who are having to vacate their position because of Brexit.

The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."

Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.

As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.

Informa UK Limited is a company registered in England and Wales with company number 1072954 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Informa UK Limited is part of Informa PLC.